Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid Spotlight: Trump Announces Plans For More Spending As Congress Introduces Two Dozen Bills

Executive Summary

Administration also plans to roll out slate of proposals to decrease drug prices and bring discounts to patients.

You may also be interested in...



Pacira’s Exparel Will Get Separate Medicare Payment; CMS Still Wants Better Opioid-Sparing Data

US Centers for Medicare and Medicaid Services proposes a change to its reimbursement policies for non-opioid pain therapies which will benefit a single product: Pacira’s Exparel. However, the broader message for that company is mixed.

Opioid Use Disorder: Is Reduced Usage A Better Endpoint Than Abstinence?

Some at patient-focused drug development meeting argue that cutting opioid use should not be considered treatment failure and that medications allowing controlled opioid use may be beneficial.

New US FDA Powers On Rx Abuse Could Be 'Tailored' By Congress, Gottlieb Suggests

At House hearing on opioid epidemic, FDA Commissioner responds to range of legislative proposals, including those aimed at agency's drug approval and safety monitoring activities.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS122740

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel